Amgen Biosimilars is committed to leveraging its extensive biotechnology experience to create high-quality biosimilars and reliably supply them to patients suffering from serious illnesses worldwide.
Positioned for Success
The story of Amgen began more than 35 years ago, thanks to a handful of scientists and investors who believed in the promise of innovative biotechnology. Since that time, our commitment to innovation has led to the launch of cutting-edge therapies and deep biologics-manufacturing expertise.
Amgen was among the first companies to develop therapeutic proteins, which can replace or augment beneficial human proteins, and monoclonal antibodies, allowing our medicines to strike disease targets with enhanced precision. Our success in this area is reflected in our product portfolio, which includes novel therapies for hard-to-treat diseases. These therapies have been used to treat millions of patients, and with the growth of Amgen’s biosimilars portfolio, there is an opportunity to treat many more.
Amgen is proud to have reached millions of people with our products. Learn more about Amgen's medicines and our commitment to biosimilars.